Compare RCKT & MBVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RCKT | MBVI |
|---|---|---|
| Founded | 1999 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 394.2M | 441.2M |
| IPO Year | 2014 | 2025 |
| Metric | RCKT | MBVI |
|---|---|---|
| Price | $2.62 | $10.24 |
| Analyst Decision | Buy | |
| Analyst Count | 14 | 0 |
| Target Price | ★ $29.73 | N/A |
| AVG Volume (30 Days) | ★ 1.7M | 50.5K |
| Earning Date | 05-04-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 26.37 | N/A |
| EPS | ★ 0.66 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $64.28 | N/A |
| P/E Ratio | $4.08 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.53 | $9.99 |
| 52 Week High | $5.45 | $10.25 |
| Indicator | RCKT | MBVI |
|---|---|---|
| Relative Strength Index (RSI) | 27.44 | 60.33 |
| Support Level | N/A | $9.99 |
| Resistance Level | $3.67 | $10.25 |
| Average True Range (ATR) | 0.23 | 0.01 |
| MACD | -0.10 | -0.00 |
| Stochastic Oscillator | 2.89 | 66.67 |
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
M3-Brigade Acquisition VI Corp is a newly incorporated blank check company.